Establishing the first southern Chinese haplobank of clinical-grade hiPSCs

Human pluripotent stem cells (PSCs) and their derivatives hold great potential in regenerative cell therapies. Establishing GMP-compliant PSC banks is a critical step in the manufacturing processes of PSC-derived cell products.

In this webinar, Camie Chan will discuss how cell therapies have emerged as a promising next-generation modality for many incurable diseases. In her talk on “Establishing the first southern Chinese haplobank of clinical-grade hiPSCs”, she will illustrate how Xellera has established the first commercial cGMP facility for cell and gene products in Hong Kong. By analyzing the HLA diversity of the southern Chinese population, Xellera has identified donors that are homozygous for the most frequent HLA-A,B,C, and DRB1 combination. The top seven human induced pluripotent stem cell (hiPSC) lines of the haplobank are expected to cover approximately 30% of the southern Chinese population, offering an off-the-shelf approach for allogeneic transplantation of hiPSC-derived cell therapies.

She will be joined by Chao Sheng, who will introduce the established workflows from Miltenyi Biotec for automated and closed human PSC expansion and differentiation using the CliniMACS Prodigy® Adherent Cell Culture process and the iPS-Brew GMP Medium.

• Considerations for generating clinical-grade induced pluripotent stem cells (iPSCs)
• Prospects for using iPSCs as universal allogenic resources for advanced therapies
• How to realize PSC expansion and differentiation using a closed and automated system

Camie Chan

CEO at Xellera Therapeutics

Camie received her MSc in Medical Sciences and PhD in Immunology from the University of Toronto, followed by her postdoctoral fellowship at the Sydney Kimmel Cancer Research Center of Johns Hopkins University. She subsequently became Assistant Professor at the University of California, Davis in 2006. She has received numerous research funding and awards including the National Institute of Allergy and Infectious Diseases (NIAID) Developmental Research Grant and the University of California Cancer Research Award. In 2016, she joined Novoheart, a global biotech company specializing in bioengineered human hearts for disease modeling and drug discovery, as the Chief Operating Officer. In 2019, she joined Xellera Therapeutics as Chief Operating Officer and has spearheaded the first commercial cGMP facility for cell and gene therapy products in Hong Kong.

Chao Sheng

Expert for Regenerative Medicine Manufacturing at Miltenyi Biotec

Chao conducted his PhD projects at the Chinese Academy of Sciences in Beijing, China. He then continued his postdoctoral research at the University of Bonn and the German Center for Neurodegenerative Diseases in Bonn, Germany, where he established human stem cell models for his research on cellular fate reprogramming, disease modeling, and drug discovery. Chao joined Miltenyi Biotec in 2018, and currently, works with his colleagues to develop automated, closed, and scalable manufacturing solutions for human pluripotent stem cells and their derivatives on the CliniMACS Prodigy® platform.

Watch now

SPEAKERS

Camie Chan

CEO at Xellera Therapeutics

Chao Sheng

Expert for Regenerative Medicine Manufacturing at Miltenyi Biotec

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 60

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 39

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 38

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 31

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 25

Days

Register